---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-047433"
form_type: "8-K"
ticker: "XFOR"
cik: "0001501697"
company_name: "X4 Pharmaceuticals, Inc"
filed_at: "2024-11-13T23:59:59+00:00"
generated_at: "2026-05-30T00:53:19.251296+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# X4 reports positive Phase 2 mavorixafor data: ANC normalized, G-CSF reduced 70% in chronic neutropenia

## Summary
- Mavorixafor monotherapy durably increased mean ANC to normal levels at Month 3 (n=9) and Month 6 (n=8).
- Severe CN patients achieved >2-fold mean ANC increase over 6 months (n=4).
- G-CSF dose reduced in 9/12 eligible patients; mean reduction 52% at Month 3, 70% at Month 6 with normal ANC.
- Neutrophil functionality sub-study: mean % functional neutrophils comparable to healthy donors after 6 months.
- No drug-related serious adverse events; mavorixafor generally well tolerated as monotherapy and combination.

## SEC filing metadata
- accession: 0001628280-24-047433
- form_type: 8-K
- ticker: XFOR
- cik: 0001501697
- company_name: X4 Pharmaceuticals, Inc
- filed_at: 2024-11-13T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1501697/000162828024047433/0001628280-24-047433-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1501697/000162828024047433/xfor-20241113.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-047433
- JSON: https://secwatch.observer/filing/0001628280-24-047433.json
- Plain text: https://secwatch.observer/filing/0001628280-24-047433.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.